BELLUS Health

101 articles about BELLUS Health

• 

  9 Top M&As in the First Half of 2023

  6/28/2023

  Despite a challenging economic climate and gloomy forecast, 2023 has still notched some mega-deals for biopharmas. BioSpace highlights the biggest deals in the industry this year.

• BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

  5/16/2023

  BELLUS Health Inc. announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting of shareholders of BELLUS on June 16, 2023.

• BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

  5/12/2023

  BELLUS Health Inc. reported its financial and operating results for the quarter ended March 31, 2023.

• BELLUS Health Announces Meeting Updates

  4/26/2023

  BELLUS Health Inc. has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement.

• 

  GSK Makes $2B Play to Challenge Merck in Chronic Cough Market

  4/18/2023

  The acquisition of Bellus Health will give GSK access to camlipixant, a potentially best-in-class P2X3 antagonist for chronic cough.

• BELLUS Health Reports Year 2022 Financial Results and Business Highlights

  3/21/2023

  BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.

• BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

  3/1/2023

  BELLUS Health Inc. today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held March 6 - 8, 2023 in Boston, MA.

• BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting

  2/8/2023

  BELLUS Health Inc. announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023.

• BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

  11/14/2022

  BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitivity indications, reported its financial and operating results for the third quarter ended September 30, 2022.

• BELLUS Health to Participate in Two Upcoming November 2022 Healthcare Investor Conferences

  11/10/2022

  BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.

• BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

  10/10/2022

  BELLUS Health Inc. today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022.

• BELLUS Health to Present at the H.C. Wainwright Annual Global Investment Conference 2022

  9/6/2022

  BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.

• BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

  8/22/2022

  BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society (“ERS”) International Congress 2022.

• BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States

  7/18/2022

  BELLUS Health Inc. announced that it has completed its previously-announced underwritten public offering in Canada and the United States of 16,540,541 common shares at a price to the public of US$9.25 per common share.

• Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough

  7/12/2022

  CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively.

• BELLUS Health to Participate in the William Blair Biotech Focus Conference

  7/5/2022

  BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the William Blair Biotech Focus Conference.

• BELLUS Health to Participate in the Jefferies Healthcare Conference

  6/1/2022

  BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10, 2022.

• BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

  5/11/2022

  BELLUS Health Inc. reported its financial and operating results for the first quarter ending March 31, 2022.

• BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

  5/2/2022

  BELLUS Health Inc. today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 Conference.

• BELLUS Health to Participate in Multiple Upcoming Investor Conferences

  4/25/2022

  BELLUS Health Inc. announced that the Company’s management team will participate in multiple upcoming investor conferences.